Beijing Beilu Pharmaceutical (300016) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.032x

Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥74.66 Million ≈ $10.93 Million USD) by net assets (CN¥2.37 Billion ≈ $346.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Beijing Beilu Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Beijing Beilu Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Beijing Beilu Pharmaceutical carry for a breakdown of total debt and financial obligations.

Beijing Beilu Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Shenzhen Kaizhong Precision Technology Co Ltd
SHE:002823
0.082x
Gold Royalty Corp.
NYSE MKT:GROY
0.004x
Apogee Enterprises Inc
NASDAQ:APOG
0.057x
Jiangsu Luokai Mechanical & Electrical Co Ltd Class A
SHG:603829
0.161x
Cantaloupe Inc
NASDAQ:CTLP
0.012x
Jiangxi Salt Industry Group Co. Ltd. A
SHG:601065
N/A
Aspen Group
AU:APZ
0.021x
Westlake Chemical Partners LP
NYSE:WLKP
0.150x

Annual Cash Flow Conversion Efficiency for Beijing Beilu Pharmaceutical (2006–2024)

The table below shows the annual cash flow conversion efficiency of Beijing Beilu Pharmaceutical from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Beijing Beilu Pharmaceutical (300016) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥1.83 Billion
≈ $267.71 Million
CN¥163.02 Million
≈ $23.86 Million
0.089x +172.27%
2023-12-31 CN¥1.79 Billion
≈ $261.39 Million
CN¥58.46 Million
≈ $8.55 Million
0.033x -50.75%
2022-12-31 CN¥1.92 Billion
≈ $281.43 Million
CN¥127.81 Million
≈ $18.70 Million
0.066x +27.42%
2021-12-31 CN¥2.08 Billion
≈ $305.05 Million
CN¥108.73 Million
≈ $15.91 Million
0.052x -43.93%
2020-12-31 CN¥1.89 Billion
≈ $276.87 Million
CN¥176.00 Million
≈ $25.75 Million
0.093x -13.95%
2019-12-31 CN¥1.45 Billion
≈ $212.25 Million
CN¥156.81 Million
≈ $22.95 Million
0.108x -25.83%
2018-12-31 CN¥1.21 Billion
≈ $176.45 Million
CN¥175.75 Million
≈ $25.72 Million
0.146x +7.54%
2017-12-31 CN¥1.07 Billion
≈ $156.46 Million
CN¥144.92 Million
≈ $21.21 Million
0.136x +60.46%
2016-12-31 CN¥901.69 Million
≈ $131.95 Million
CN¥76.17 Million
≈ $11.15 Million
0.084x -2.56%
2015-12-31 CN¥932.63 Million
≈ $136.47 Million
CN¥80.85 Million
≈ $11.83 Million
0.087x +37.19%
2014-12-31 CN¥666.33 Million
≈ $97.51 Million
CN¥42.11 Million
≈ $6.16 Million
0.063x -14.55%
2013-12-31 CN¥559.38 Million
≈ $81.86 Million
CN¥41.37 Million
≈ $6.05 Million
0.074x +69.54%
2012-12-31 CN¥523.96 Million
≈ $76.67 Million
CN¥22.86 Million
≈ $3.34 Million
0.044x -53.12%
2011-12-31 CN¥491.47 Million
≈ $71.92 Million
CN¥45.73 Million
≈ $6.69 Million
0.093x +15.98%
2010-12-31 CN¥467.62 Million
≈ $68.43 Million
CN¥37.51 Million
≈ $5.49 Million
0.080x -39.92%
2009-12-31 CN¥433.71 Million
≈ $63.46 Million
CN¥57.91 Million
≈ $8.47 Million
0.134x +473.67%
2008-12-31 CN¥133.23 Million
≈ $19.50 Million
CN¥-4.76 Million
≈ $-696.67K
-0.036x -126.30%
2007-12-31 CN¥90.33 Million
≈ $13.22 Million
CN¥12.28 Million
≈ $1.80 Million
0.136x -50.49%
2006-12-31 CN¥71.59 Million
≈ $10.48 Million
CN¥19.65 Million
≈ $2.88 Million
0.274x --

About Beijing Beilu Pharmaceutical

SHE:300016 China Drug Manufacturers - Specialty & Generic
Market Cap
$780.01 Million
CN¥5.33 Billion CNY
Market Cap Rank
#10279 Global
#2966 in China
Share Price
CN¥9.47
Change (1 day)
-1.66%
52-Week Range
CN¥6.60 - CN¥11.26
All Time High
CN¥27.25
About

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more